Biostar Pharmaceuticals partners with Shaanxi University of Chinese Medicine to co-develop liver cancer drug

In recent years, the new cancer cases and fatalities have been increasing sharply around the world, with China bearing the heaviest toll of this increase.

The latest edition of the World Cancer Report also shows that, liver cancer, among lung, oesophagus and stomach, were the most common cancers for Chinese population. In 2012, about 50% of global liver cancer cases and 51% of worldwide deaths caused by liver cancer were recorded in China.

One of major causes for such alarming statistics is that China has more than 40 million Hepatitis B patients. Many of these Hepatitis B patients did not receive timely and proper care and treatment and, which as a result, lead to worsening their health conditions, including, among others, liver cancer.

The research of applying Oleanic acid to treat liver cancer has been well reported in United States in recent years. Biostar’s research scientists has discovered that the "AO" factor existed in the Oleanic acid was remarkably effective in killing the Hepatitis B virus (HBV), and it may also be used to kill the cancer cells.

Biostar Pharmaceuticals chairman and CEO Ronghua Wang noted the company is very glad to team up Shaanxi University of Chinese Medicine to jointly develop Oleanolic Acid injection drug for liver cancer after numerous rounds of market research and in-depth discussion with many research institutions in China.

"Research and development of a new medicine to treat and, hopefully, cure liver cancer has been the dream of our company for years. In order to make it successful, we intend to invest large amount of capital and resources to support this exciting research project in the near future," Wang added.